Oncogene-Driven Metastatic NSCLC: Frontline Treatment & Resistance Mechanisms - OncTalk 2022

Oncogene-Driven Metastatic NSCLC: Frontline Treatment & Resistance Mechanisms - OncTalk 2022Подробнее

Overcoming Resistance in ALK+ or KRAS+ NSCLC - Lung Cancer OncTalk 2022Подробнее

Overcoming Resistance in EGFR+ NSCLC - Lung Cancer OncTalk 2022Подробнее

Resistance Mechanisms in EGFR+ NSCLCПодробнее

Dr. Shum on Mechanisms of Resistance in Oncogene-Driven NSCLCПодробнее

ICBioMed 2022– Current Options for the Treatment of Advanced or Metastatic NSCLCПодробнее

Strategies to Overcome Resistance - Lung Cancer OncTalk 2022Подробнее

Overcoming Resistance in ROS1+, RET+, or BRAF+ NSCLC - Lung Cancer OncTalk 2022Подробнее

Molecular Biomarker Revolution in Metastatic NSCLCПодробнее

Resistance Mechanisms and Sequencing for EGFR+ NSCLCПодробнее

Treatments Algorithms for Advanced NSCLC - Lung Cancer OncTalk 2022Подробнее

Checkpoint inhibitors for lung cancer: combating resistanceПодробнее

NSCLC: EGFR Inhibition and Resistance MechanismsПодробнее

ILCN Multidisciplinary Forum: Understanding Treatment Options and Resistance in EGFR-positive NSCLCПодробнее

Mechanisms of Resistance to TKI in NSCLCПодробнее

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLCПодробнее

Metastatic Lung Cancer | 2022 OneOncology ConferenceПодробнее

Current Treatments for Oligometastatic NSCLC - Lung Cancer OncTalk 2022Подробнее